Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series.
J Neurol Sci
; 439: 120306, 2022 08 15.
Article
in English
| MEDLINE | ID: covidwho-1867404
ABSTRACT
We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclonal antibodies. In particular, we showed the possibility to use monoclonal antibodies to speed-up recovery from COVID-19 in MS, in the absence of any COVID-19 residuals or MS changes (e.g., relapses or disability).
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Multiple Sclerosis
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Language:
English
Journal:
J Neurol Sci
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS